=Teva Pharma (TEVA) reported earnings on Thur 7 May 20 (b/o)

Teva Pharma beats by $0.17, beats on revs; reaffirms FY20 EPS in-line, revs in-line

Reports Q1 (Mar) earnings of $0.76 per share, excluding non-recurring items, $0.17 better than the S&P Capital IQ Consensus of $0.59; revenues rose 5.0% year/year to $4.36 bln vs the $4.15 bln S&P Capital IQ Consensus.

Co issues in-line guidance for FY20, sees EPS of $2.30-2.55 vs. $2.44 S&P Capital IQ Consensus; sees FY20 revs of $16.6-17.0 bln vs. $16.74 bln S&P Capital IQ Consensus.